Switch from antagonist to agonist of the androgen receptor blocker bicalutamide is associated with prostate tumour progression in a new model system

Advanced prostate cancer is treated by androgen ablation and/or androgen receptor (AR) antagonists. In order to investigate the mechanisms relevant to the development of therapy-resistant tumours, we established a new tumour model which closely resembles the situation in patients who receive androge...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Principais autores: Zoran Čulig, Jens Hoffmann, Martin Erdel, Iris E. Eder, Alfred Hobisch, A Hittmair, G. Bartsch, Gerd Utermann, M. R. Schneider, Karsten Parczyk, Helmut Klocker
Formato: Artigo
Idioma:Inglês
Publicado em: 1999
Acesso em linha:https://doi.org/10.1038/sj.bjc.6690684
https://www.nature.com/articles/6690684.pdf
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!